Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Apr 15, 2010

Premium

Title: Oligoribonucleotides and Ribonucleases for Cleaving RNA

Patent Number: 7,695,902

Filed: Feb. 20, 2002

Inventor: Stanley Crooke, Isis Pharmaceuticals

The patent, its abstract states, claims "oligomeric compounds, including oligoribonucleotides and oligoribonucleosides … that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strands, as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics.

"Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases," the abstract adds. "Such a ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins."


Title: Compositions and Methods for Generating Short Double-Stranded RNA Using Mutated RNase III

Patent Number: 7,695,964

Filed: Jan. 21 2005 PCT Filed: Jan. 21, 2005

Lead Inventor: Claude Maina, New England Biolabs

The invention, the patent's abstract states, comprises "compositions and methods … for preparing an hsiRNA mixture and for silencing of gene expression in vivo. The composition relates to a mutant RNase III. The methods are directed to reacting a preparation of dsRNA with an effective amount of a mutant RNase III to produce the hsiRNA mixture."


Title: Inhibition of Gene Expression Using RNA Interfering Agents

Patent Number: 7,696,179

Filed: Oct. 29, 2003 PCT Filed: Oct. 29, 2003

Lead Inventor: Judy Lieberman, Harvard University

The invention, the patent's abstract states, "is based, at least in part, on the discovery of compositions and methods for the treatment and prevention of infectious diseases or disorders, e.g., HIV infection, AIDS, and AIDS-related diseases. In particular, the … invention pertains to methods of modulating cellular gene expression or protein activity, e.g., CCR5, gene expression or protein activity, and/or gene expression or protein activity of a gene or sequence of an infectious agent, in order to treat or prevent infectious diseases or disorders, HIV infection, AIDS, or an AIDS-related disease or disorder.

"In one embodiment the combination of an RNA interfering agent targeting a cellular gene in combination with an RNA interfering agent targeting a gene or sequence of an infectious agent results in prolonged prevention of infection by an infectious agent," the abstract states. "The … invention is based on the identification of novel RNA interference agents, e.g., siRNA molecules, which target cellular genes, e.g., chemokine receptors, e.g., the CCR5 gene, and result in inhibition of target gene expression on target gene expressing cells, thereby inhibiting entry of infectious agents, e,g., HIV infection into target cells, prevention infection, and/or suppressing replication in established infection."


Title: Bioinformatically Detectable Human Herpesvirus 5 Regulatory Gene

Patent Number: 7,696,334

Filed: Aug. 28, 2003

Inventor: Isaac Bentwich, Rosetta Genomics

The invention, the patent's abstract states, relates to "a group of novel viral RNA regulatory genes, here identified as 'viral genomic address messenger genes' or 'VGAM genes', and as 'genomic record' or 'GR' genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing, and treating viral disease.

"Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity," the abstract adds.


Title: Bioinformatically Detectable Group of Novel Viral Regulatory Genes and Uses Thereof

Patent Number: 7,696,342

Filed: Aug. 27, 2003

Inventor: Isaac Bentwich, Rosetta Genomics

The invention, the patent's abstract states, relates to "a group of novel viral RNA regulatory genes, here identified as 'viral genomic address messenger genes' or 'VGAM genes', and as 'genomic record' or 'GR' genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing, and treating viral disease.

"Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity," it adds.


Title: siRNA Targeting Complement Factor B

Patent Number: 7,696,344

Filed: Dec. 7, 2006

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes."


Title: Nucleic Acid Constructs and Methods for Specific Silencing of H19

Application Number: 20100086526

Filed: Jan. 16, 2008 PCT Filed: Jan. 16, 2008

Inventor: Abraham Hochberg, Hebrew University of Jerusalem

The invention, the patent application's abstract states, "is directed to recombinant constructs and methods for treating pathological conditions associated with H19 expression, such as tumors characterized by up-regulated expression of H19 RNA. Specifically, the recombinant constructs of the invention comprise at least one nucleic acid sequence encoding a small interfering RNA molecule directed to H19, the nucleic acid sequence being operably linked to at least one H19-specific transcription-regulating sequence. Vectors comprising these constructs, pharmaceutical compositions comprising them, and therapeutic methods of using same are also provided."


Title: Compositions and Methods for Treating Conditions Associated with Ceramide Biosynthesis

Application Number: 20100086543

Filed: Sept. 23, 2009

Inventor: Daniela Salvemini, Saint Louis University

The invention, the patent application's abstract states, comprises a "pharmaceutical composition and a method for reducing, preventing, or delaying the development of a biological condition associated with administration of an opioid drug, in particular, tolerance to and/or physical dependence on an opioid drug. The pharmaceutical composition includes an opioid drug, a ceramide biosynthesis inhibitor, and a pharmaceutically acceptable carrier. The method of treatment involves administration of an opioid drug and a ceramide biosynthesis inhibitor.

"Also provided are a method of screening for an agent that reduces, prevents, or delays the development of tolerance to and/or physical dependence on an opioid drug, as well as compositions comprising a dsRNA for inhibiting ceramide biosynthesis in a cell and a vector for expressing a shRNA for inhibiting ceramide biosynthesis in a cell," it adds.


Title: Preventative/Therapeutic Agent for Cancer

Application Number: 20100086911

Filed: March 2, 2006 PCT Filed: March 2, 2006

Lead Inventor: Ryosuke Katsuyama, Kyoto University

The patent application, its abstract states, claims the "identification of a novel target molecule for preventing [or] treating cancer and a preventive [or] remedy agent for cancer [that] targets the molecule."

Specifically, this molecule is an "agent for promoting the apoptosis in cancer cells and/or inhibiting the growth of cancer cells and a preventive/remedy agent for cancer," comprised of an antibody against a predefined protein, an antisense polynucleotide such as an siRNA of the protein, and a substance controlling the expression and/or activity of the protein, the abstract adds.

Also claimed is a method for "screening for a substance that promotes apoptosis in cancer cells and/or inhibits the growth of cancer cells and a preventive [or] remedy substance for cancer, in which the method comprises using a protein, an antibody against the protein, or a polynucleotide encoding the protein."


Title: siRNA Targeting Superoxide Dismutase 1

Application Number: 20100087334

Filed: Oct. 29, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for SOD1."


Title: siRNA Targeting Spleen Tyrosine Kinase

Application Number: 20100087335

Filed: Nov. 23, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes."


Title: Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes

Application Number: 20100087508

Filed: Sept. 1, 2009

Lead Inventor: David Bumcrot, Alnylam Pharmaceuticals

"This invention relates to compositions containing double-stranded ribonucleic acid in a SNALP formulation, and methods of using the compositions to inhibit the expression of the Eg5 and vascular endothelial growth factor, and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer," the patent application's abstract states.


Titles: microRNA Molecules

Application Numbers: 20100087512, 20100087513

Filed: Aug. 31, 2009

Lead Inventor: Thomas Tuschl, Rockefeller University

"In Caenorhabditis elegans, lin-4 and let-7 encode 22- and 21-nucleotide RNAs, respectively, that function as key regulators of developmental timing," the patent applications' abstracts state.
"Because the appearance of these short RNAs is regulated during development, they are also referred to as 'small temporal RNAs.' We show that many more 21- and 22-[nucleotide] expressed RNAs, termed microRNAs, exist in invertebrates and vertebrates, and that some of these novel RNAs, similar to let-7 stRAN, are also highly conserved. This suggests that sequence-specific post-transcriptional regulatory mechanisms mediated by small RNAs are more general than previously appreciated."

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.